Adelene PerkinsChair, President & CEO
Adelene Perkins has served as Infinity Pharmaceuticals’ President and CEO since 2009 and as board chair since 2012. She has played an integral role in building the company, leading its transition from a platform to a product-based organization. She was the principal figure in structuring and restructuring Infinity's strategic relationships which have played a critical role in developing the company’s current product portfolio. Adelene has more than 25 years of international business experience in the biopharmaceutical industry, focused on building and leading high-caliber, cross-functional teams, corporate strategy licensing and business development, strategic finance, and product life cycle management. Adelene joined Infinity from TransForm Pharmaceuticals where she was an early member of the management team that built the company prior to its acquisition by J&J. Prior to Transform she was vice president of emerging businesses at Genetics Institute, now part of Pfizer. She joined GI from Bain & Company where she provided strategic and operational advice to clients in the healthcare industry. Adelene holds an M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is on the Boards of the Massachusetts Life Sciences Center, the Massachusetts Biotechnology Council, BIO (the Biotechnology Industry Organization), and the Villanova University College of Engineering, and is Vice Chairman of the Board of Project Hope.